This site is intended for healthcare professionals
News

FDA priority review of BLA for beti-cel gene therapy for patients with beta-thalassemia.

Read time: 1 mins
Last updated:23rd Nov 2021
Published:23rd Nov 2021
bluebird bio, Inc. announced that the FDA has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review.

Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with beta-thalassemia across all genotypes who require regular red blood cell (RBC) transfusions. If approved, beti-cel will be the first one-time treatment that addresses the underlying genetic cause of disease for patients living with beta-thalassemia in the U.S.—offering an alternative to regular RBC transfusions and iron chelation therapy. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of May 20, 2022.

The BLA for beti-cel is based on data from bluebird bio’s Phase III studies HGB-207 (Northstar-2) and HGB-212 (Northstar-3), the Phase 1/II HGB-204 (Northstar) and HGB-205 studies, and the long-term follow-up study LTF-303. Together, these studies represent more than 220 patient-years of experience with beti-cel. As of March 9, 2021, the results include a total of 63 pediatric, adolescent and adult patients, including long-term efficacy and safety results in two patients with more than seven years follow-up. Additional data through August 2021 will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021.

Condition: Beta-thalassemia
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.